Across TCGA pan-cancer cohorts, RBMY2EP Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated RBMY2EP data layer compared with 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher RBMY2EP Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RBMY2EP expression acts as an unfavorable survival marker.

LUSC are the cancer types where RBMY2EP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.104	0.760	<.001	24	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: RBMY2EP tumor-vs-normal RNA expression · all RBMY2EP data types